Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.75 GBX | 0.00% | 0.00% | -11.76% |
Apr. 15 | Fusion Antibodies inks commercial contract for OptiPhage library | AN |
Apr. 15 | Fusion Antibodies Secures Contract to Set Up OptiPhage Library | MT |
Sales 2024 * | 1.15M 1.44M | Sales 2025 * | - | Capitalization | 3.58M 4.47M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.25M | Net income 2025 * | - | EV / Sales 2024 * | 3.11 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.34
x | P/E ratio 2025 * |
-
| Employees | 48 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.63% |
1 month | -5.06% | ||
3 months | -16.67% | ||
6 months | -34.78% | ||
Current year | -11.76% |
Managers | Title | Age | Since |
---|---|---|---|
Adrian Kinkaid
CEO | Chief Executive Officer | 57 | 22-08-14 |
Stephen Smyth
DFI | Director of Finance/CFO | 49 | 23-08-23 |
Simon Douglas
CHM | Chairman | 65 | 05-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Colin Walsh
BRD | Director/Board Member | 68 | 06-12-31 |
Simon Douglas
CHM | Chairman | 65 | 05-12-31 |
Richard Buick
CTO | Chief Tech/Sci/R&D Officer | 47 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 3.75 | 0.00% | 220,253 |
24-04-24 | 3.75 | -1.32% | 187,413 |
24-04-23 | 3.8 | 0.00% | 533,374 |
24-04-22 | 3.8 | +1.33% | 321,656 |
24-04-19 | 3.75 | 0.00% | 138,126 |
Delayed Quote London S.E., April 25, 2024 at 11:35 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.76% | 4.45M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- FAB Stock